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delivery, reperfusion of ischemic intestines will only com-
pound any mucosal barrier dysfunction. Previous reports
have implicated both mast cells and polymorphonuclear
leukocytes in the pathogenesis of this type of IR injury.
Furthermore, disturbances of the delicate intestinal micro-
circulation are known to be associated with the ultimate
development of multiple organ dysfunction syndrome.8
Dopexamine hydrochloride, a synthetic catecholamine,
has dopaminergic receptor agonist properties at both the
dopamine 1 and 2 receptors combined with a potent β2
receptor agonist activity. It has no α or direct β1 effects but
exhibits potent uptake-1 inhibition, thus potentiating neu-
ronally released noradrenaline.9-11 Its unique combination
of pharmacologic properties translates into a clinical profile
of afterload reduction, direct and indirect positive inotro-
pism, and potentially both renal and splanchnic vascular bed
dilatation. These beneficial effects have been applied to a
variety of clinical settings in the past, including heart failure
and low output states.12-15 However, interest in dopexamine
has grown, particularly following recent studies suggesting
its anti-inflammatory role, both in humans and animals, in
cases of sepsis and in critically ill surgical patients.16-20 This
role cannot be explained purely by its β2 agonist properties.
The aim of our study, which was a single-center side
arm of a multicenter, prospective, randomized, placebo-
controlled study to examine the effect of dopexamine on
renal function after elective aortic surgery, was designed to
Since the first report by Moore in 1954,1 colonic
ischemia, a well-recognized complication of abdominal
aortic surgery, is associated with increased mortality and
morbidity rates and has an incidence ranging from 2.8% to
60% depending on diagnostic criteria, case selection, and
data collection.2-6 In a recently reported prospective study,
we found an incidence of 30% in a group of 56 patients
undergoing elective infrarenal aortic surgery, when based
on histologic findings.7 As yet, the pathogenesis underly-
ing this complication and its systemic consequences is not
fully understood but is likely to be the result of an
ischemia reperfusion (IR) injury. Although gut mucosa is
exquisitely sensitive to a reduction in local tissue oxygen
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Purpose: Colonic ischemia after aortic surgery is associated with increased mortality and morbidity rates. This study was
conducted as a single-center side arm to a multicenter, randomized, placebo-controlled study to evaluate the effect of
dopexamine hydrochloride on its incidence.
Methods: Thirty patients, mean age 65.1 years (range, 46-84), undergoing elective infrarenal aortic surgery were
entered. Preoperative hemodynamic and respiratory parameters were optimized. Patients were then randomly assigned
to receive a perioperative infusion of dopexamine at 2 µg/kg per minute (n = 12) or 0.9% saline placebo (n = 18). All
patients underwent colonoscopy and biopsy preoperatively and 1 week postoperatively. Specimens were assessed for evi-
dence of mucosal ischemia, presence of mast cell tryptase, myeloperoxidase activity, and both the inducible and endothe-
lial isoforms of nitric oxide synthase.
Results: There was no significant difference in perioperative fluid and blood requirements or hemodynamic and respi-
ratory parameters between the two groups. However, there was significantly less evidence of mucosal ischemic changes
in dopexamine-treated patients (n = 1) compared with placebo (n = 8) (P = .049). Furthermore, when preoperative
biopsies were compared with those performed 1 week postoperatively, nine (50%) patients in the placebo group and
two (16.7%) in the dopexamine group scored worse. Although there was no significant difference in inflammatory
markers between the two groups, both mast cell tryptase and myeloperoxidase expression were increased in patients
with histologic evidence of ischemia (P < .05). Furthermore, inducible nitric oxide synthase staining within the vascu-
lar (P = .001) and lamina propria (P < .05) components of the mucosa was also significantly greater.
Conclusion: A perioperative dopexamine infusion affords significant histologic protection to colonic mucosa after aor-
tic surgery. (J Vasc Surg 2001;33:758-63.)
examine the effect of a perioperative infusion of dopexam-
ine hydrochloride on colonic mucosa after infrarenal aor-
tic cross-clamping.
METHODS
After ethical committee approval, written informed
consent was obtained from all patients entered into the
main study. Additional written consent was taken from
patients for the side arm of the study. Of 36 patients
included in the main study at this site, 30, with a mean age
65.1 years (range, 46-84) undergoing elective infrarenal
aortic surgery, were entered to this side arm study.
Exclusion criteria for the main study included a history of
tachyarrhythmias or myocardial infarction within the previ-
ous 6 months, and those who had previous aortic surgery
or a colonic pathologic condition were also excluded from
entering the side arm study. Patients were randomly allo-
cated by site, with the use of sealed envelopes, to receive an
infusion of either dopexamine hydrochloride (Speywood
Pharmaceuticals Ltd, Maidenhead, Berkshire, UK) at a rate
of 2 µg/kg per minute (n = 12) or placebo (0.9% saline) at
a similar rate (n = 18).
All patients were stabilized preoperatively with the aid
of arterial and central venous catheters, blood assays, flu-
ids, and supplementary oxygen to achieve predetermined
goals: central venous pressure (CVP) of 8 to 10 cm H2O,
mean arterial blood pressure of 90 mm Hg, hemoglobin
level of 10 g/dL, and oxygen saturation of 95%. An infu-
sion of dopexamine or placebo was started at the induc-
tion of anesthesia and continued for 24 hours. A standard
general anesthetic technique was used in all cases. The
evening before surgery, patients were given a phosphate
enema to evacuate the distal colon and rectum. After
induction of anesthesia, patients were placed in the left lat-
eral position, and a limited colonoscopy was performed
with an Olympus CF-10L colonoscope (Olympus Optical,
London, UK). Biopsies were then taken at 20, 30, and 40
cm from the anal verge and identified with different code
numbers. A repeat biopsy was performed 1 week postop-
eratively in all patients to minimize discomfort. All opera-
tions were performed with a standard technique:
aneurysms by inlay of a straight or bifurcated graft and
occlusive disease by end-to-side proximal anastomosis.
Operative details including cross-clamp time, patency or
ligation of mesenteric and internal iliac vessels, and hemo-
dynamic variables were recorded. All patients had preser-
vation of at least one internal iliac artery. Routine
postoperative management involved 24-hour observation
and monitoring in the intensive care unit with intravenous
morphine patient-controlled analgesia for pain control and
fluids including blood products provided as necessary.
Histopathologic specimens were fixed in 10% formalin and
processed to paraffin wax. Three 5-µm sections were then
cut and fixed on each slide. These were stained with hema-
toxylin and eosin and immunohistochemically with an
indirect immunoperoxidase technique for expression of
specific markers of inflammatory activation including:
myeloperoxidase (DAKO Ltd, Cambridgeshire, UK);
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mast cell tryptase (MCT) (DAKO Ltd), which binds to
secretory granules in degranulated mast cells; and isoforms
of both the inducible nitric oxide synthase (iNOS)
(Serotec, Oxford, UK) and endothelial nitric oxide syn-
thase (eNOS) (Serotec). The primary antibody was omit-
ted for negative controls. Positive controls included
sections of inflammatory exudates for myeloperoxidase,
normal tonsil and spleen for MCT, and scleroderma skin
for both eNOS and iNOS. Clinical evaluation of speci-
mens was performed independently by two histopatholo-
gists. A grade correlating the type and severity of ischemic
changes was recorded (Table I). All immunohistochemical
sections were assessed with a semiquantitative method and
Table I. Grading system applied to histopathologic










Table III. Evidence of mucosal ischemia as assessed with
H+E and MPO: comparison between dopexamine-
treated and placebo groups 
Dopexamine Placebo
(n = 12) (n = 18)
H+E
Preoperative score (mean ± SD) 1.25 ± 0.45 1.11 ± 0.32
Postoperative score (mean ± SD) 1.25 ± 0.62 2.56 ± 2.01
Number better (%) 3 (25) 0 (0)
Number same (%) 7 (58.3) 9 (50)
Number worse (%) 2 (16.7) 9 (50)
MPO
Preoperative score (mean ± SD) 0.17 ± 0.39 0.18 ± 0.39
Postoperative score (mean ± SD) 0.42 ± 0.67 0.76 ± 0.97
Number better (%) 1 (8.3) 1 (5.5)
Number same (%) 8 (66.7) 10 (55.6)
Number worse (%) 3 (25) 7 (38.9)
H+E, Hematoxylin and eosin; MPO, myeloperoxidase.
Table II. Patient demographic data (mean ± SD)
Dopexamine group Placebo group
(n = 12) (n = 18)
Age (y) 67.7 ± 9.4 63.4 ± 8.1
Sex (male:female) 8:4 14:4
Mean weight (kg) 70.4 ± 6.9 69.8 ± 15.9
Aneurysmal disease 3 8
Occlusive disease 9 10
given a score according to the degree of the staining as
absent (0), mild (1), moderate (2), and severe (3). In the
case of both iNOS and eNOS, scores were assigned in a
similar fashion to the degree of expression within the var-
ious elements of the mucosa (vascular endothelium—v,
cytoplasm of epithelial cells—c, nucleus of epithelial
cells—n, membrane of epithelial cells—m, lamina pro-
pria—l). In cases where scores given by both histopathol-
ogists did not concur, agreement was reached on
reviewing and discussing the slide in question.
Summary data are expressed as mean ± SD.
Differences in proportions were tested with the χ2 or
Fisher exact test as appropriate. The Student t test was
used to compare quantitative data when the distribution
was considered to be normal. The Mann-Whitney U test
was used to compare the score representing the severity of
mucosal ischemia, as determined histologically, and the
degree of immunohistochemical staining, between treat-
ment and placebo groups. Correlation between groups of
ordinal data was assessed by calculating the Spearman rank
correlation coefficient and its associated P value. The level
for statistical significance was set at P less than .05.
RESULTS
The two groups were well matched in regard to age,
sex, and weight (Table II). The dopexamine-treated group
comprised nine patients with aortoiliac occlusive disease
and three with abdominal aortic aneurysm (AAA); the
placebo group included 10 patients with occlusive disease
and eight with AAA. Although there was no significant
difference between the two groups regarding preoperative
patency of the inferior mesenteric artery, it was routinely
ligated in 12 (100%) patients with aneurysmal disease and
in six (32%) with occlusive disease. In all cases, at least one
internal iliac artery remained patent, and no additional
revascularization procedures were performed. All patients
had preoperative biopsies with grades 1 or 2, but nine
(30%) had histologic evidence suggestive of ischemia
(grade ≥ 3) postoperatively of which only one was within
the dopexamine-treated group (P = .049, Fisher exact
test). Furthermore, the degree of mucosal ischemia was
significantly greater in the placebo group than in those
treated with dopexamine (P = .025, Mann-Whitney U
test). When preoperative biopsies were compared with
those performed 1 week postoperatively, nine (50%)
patients in the placebo group and two (16.7%) in the
dopexamine group scored worse (Table III). Although
increased myeloperoxidase activity was seen in the placebo
group 7 days postoperatively when compared with those
receiving dopexamine, this was not statistically significant.
There was one death in the placebo group from colonic
infarction at 11 days. Histologic sections demonstrated
transmural infarction, and thus immunohistochemistry
was not performed because it was not possible to differen-
tiate cell types. There were no deaths in the dopexamine-
treated group. No significant association between grade of
mucosal ischemic changes and sex, age, indication for
surgery (AAA vs aortoiliac disease), clamp time and liga-
tion or patency of the inferior mesenteric artery was found
in this series. Also, there was no significant difference
between the AAA and occlusive groups regarding fluid
(3306 ± 1326 mL vs 3127 ± 765 mL, P = .73) or blood
(481 ± 444 mL vs 379 ± 437 mL, P = .60) requirements.
Although there was a greater perioperative blood require-
ment in the placebo group, this was not statistically signif-
icant and was not associated with the grading of mucosal
ischemic changes. Furthermore, there was no significant
difference in perioperative or postoperative cardiorespira-
tory parameters (Table IV) between the two groups.
There was increased presence of both degranulated mast
cells and neutrophils in those sections with evidence of
mucosal ischemia (P < .05) (Fig 1). This was also associ-
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Table IV. Hemodynamic variables compared between dopexamine-treated and placebo groups (mean ± SD)
Dopexamine group (n = 12) Placebo group (n = 18) P value*
Preoperative baseline values
CVP (cm H20) 9.0 ± 1.2 8.7 ± 2.9 .7555
Mean blood pressure (mm Hg) 115.5 ± 13.5 116.4 ± 12.1 .8483
Mean oxygen saturation (%) 97.4 ± 1.1 96.7 ± 1.5 .1907
Mean hemoglobin (g/dL) 14.7 ± 1.1 14.3 ± 1.6 .4756
Perioperative values
CVP (cm H20) 6.6 ± 2.9 7.3 ± 3.5 .6577
Mean blood pressure (mm Hg) 101 ± 9.9 100 ± 13.1 .8305
Mean oxygen saturation (%) 97.9 ± 0.3 97.9 ± 1.2 .9487
Fluid input (mL) 2975.0 ± 720.1 3323.3 ± 1083.8 .3443
Blood given (mL) 225.0 ± 382.4 536.7 ± 430.3 .07
Postoperative values (24 h)
CVP (cm H20) 4.1 ± 4.1 6.6 ± 4.2 .156
Mean blood pressure (mm Hg) 109.6 ± 19.8 102.9 ± 13.6 .344
Mean oxygen saturation (%) 97 ± 2.1 96.9 ± 1.7 .904
Mean hemoglobin (g/dL) 10.9 ± 1.2 11.1 ± 1.8 .757
Fluid input (mL) 4256.0 ± 1905.2 4959.6 ± 2154.2 .39
Blood given (mL) 490.0 (840.8) 432.5 (463.8) .837
*Student t test.
ated with increased expression of iNOS (Fig 2) within the
vascular (P = .001) and lamina propria elements (P < .05).
However, no significant relationship was found with any
of the immunohistochemical markers of inflammatory
activation between treatment and placebo groups.
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DISCUSSION
Optimization of cardiac performance by the use of
invasive monitoring and fluid and inotrope administration
for high-risk surgical patients has been shown to reduce
morbidity and mortality rates.21 In addition, this study has
Fig 1. Immunohistochemical staining pattern in biopsy with colonic ischemia. A, Neutrophil infiltration within lamina propria (brown
staining) as seen with myeloperoxidase staining. An early crypt abscess can be identified (arrow). Original magnification ×40. B, Mast
cells identified within lamina propria by MCT (brown staining) Original magnification ×60.
A
B
were randomly given dopexamine or placebo. There was a
significant reduction in myeloperoxidase activity within the
upper gastrointestinal mucosa 72 hours after surgery in
patients treated with dopexamine. In this study we were
unable to demonstrate any significant reduction in the
expression of inflammatory markers in the dopexamine-
treated group despite the clear reduction in histologic evi-
dence of ischemic changes. One possible explanation could
be that the protection afforded by dopexamine occurs early
in the cascade of events that leads to structural damage,
and therefore, a biopsy at 7 days may have missed these
changes. However, the development of ischemic changes
was associated with both increased mast cell and neutrophil
activity. It has previously been demonstrated that degranu-
lation of mast cells is responsible for the recruitment of
neutrophils after intestinal IR injury in a rat model.23 The
finding of increased numbers of degranulated mast cells
within the colonic mucosa in this study suggests that simi-
lar mechanisms exist for the development of colonic
ischemia after aortic surgery. The significance of increased
iNOS expression in both the vascular endothelium and
lamina propria in these patients is less clear. Nitric oxide
(NO) is generated in response to tissue reperfusion
injury.24 Studies with animal models of shock have
reported both beneficial and detrimental effects of nitric
oxide synthase inhibitors.25-30 Kubes31 has previously
demonstrated that NO inhibition increased intestinal per-
meability after IR injury. In a rat model of endotoxic shock,
JOURNAL OF VASCULAR SURGERY
762 Baguneid et al April 2001
demonstrated that a perioperative infusion of dopexamine
hydrochloride can confer significant mucosal protection to
the distal colon in patients undergoing infrarenal aortic
surgery. In patients with histologic evidence of colonic
ischemia, there was a typical pattern of increased iNOS
expression, particularly within the vascular endothelium,
and increased presence of both neutrophils (myeloperoxi-
dase) and degranulated mast cells (MCT). The exact mech-
anism for this mucosal protection has not been identified
in this study but may be due to either improved mucosal
perfusion or a specific anti-inflammatory effect. The latter
hypothesis has attracted more attention recently. Boyd et
al16 demonstrated a significant reduction of the mortality
rate in a group of high-risk surgical patients receiving
dopexamine when compared with those receiving placebo,
despite an absence of increased oxygen consumption.
Smithies et al22 showed that dopexamine improved
splanchnic oxygenation independent of its systemic effects.
In a study with a porcine model of septic shock, where car-
diac output and oxygen delivery were standardized, the β2
effect of dopexamine was shown to maintain the histologic
architecture of the liver when compared with dobutamine
or fluids alone.18 In fact, in this model the α1 agonist prop-
erties of dobutamine were associated with more destruc-
tion to the liver than fluid alone. An anti-inflammatory
action in humans has recently been shown in critically ill
surgical patients.17 These patients were all undergoing
major abdominal surgery, excluding vascular surgery, and
Fig 2. Marked iNOS expression within vascular, lamina propria, and epithelial components of ischemic colonic mucosa. Original mag-
nification ×40.
iNOS induction was noted in the mucosa of both the small
and large intestines as well as in monocytes and
macrophages in multiple organs.32 Furthermore, there is
evidence that iNOS in the lung is upregulated after intesti-
nal IR injury.33 It was suggested that this may be a com-
pensatory protective response. However, the inappropriate
overproduction of NO is also known to lead to loss of vas-
cular vasomotor control and myocardial hypocontractil-
ity.34-36 The mode of action of dopexamine, with respect
to its anti-inflammatory properties, is far from clear, but
light has recently been shed by Schmidt et al20 using intra-
vital microscopy in a rat endotoxemia model. Dopexamine
administration significantly reduced leukocyte adherence
to postcapillary venules in rat mesentery, and use of a β2-
adrenoreceptor antagonist did not attenuate this effect.
However, an attenuating effect on vascular permeability
was β2-adrenoreceptor mediated. It is evident that the
actions of dopexamine extend beyond a simple hemody-
namic effect, and further work will need to focus on estab-
lishing the specific target of its anti-inflammatory effect.
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